Cell-free DNA could identify likely Rubraca responders

Cell-free DNA analysis of BRCA reversion mutations could go beyond tissue-based diagnostics to help identify high-grade ovarian cancer patients who are likely to respond to PARP inhibitor Rubraca rucaparib, according to a paper published in Cancer Discovery.

The paper was authored by researchers from Clovis Oncology Inc. (NASDAQ:CLVS), University of Washington and diagnostic companies Foundation Medicine Inc. (NASDAQ:FMI) and Guardant Health Inc. (NASDAQ:GH). Clovis markets Rubraca for ovarian cancer patients with deleterious mutations in breast cancer 1 early onset (BRCA1) or BRCA2...